Trial Profile
A clinical study of rifaximin in patients with postoperative Crohn's disease
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2018
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 05 Nov 2018 New trial record
- 29 Oct 2018 According to a Salix Pharmaceuticals media release, Salix Pharmaceuticals and Alfasigma has entered into agreement to initiate the late stage clinical program to study rifaximin in patients with postoperative Crohn's disease.